Skip to main content

Advertisement

Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy

Summary

LV mass by CMR is a powerful predictor of adverse cardiovascular outcomes in patients treated with anthracyclines.

Background

Late gadolinium enhancement (LGE) is a predictor of adverse outcomes in patients. However, limited data exist on the role of LGE, the characteristic CMR findings, and the prognostic variables in patients who develop a cardiomyopathy after treatment with anthracyclines.

Methods

LGE-CMR imaging was performed in patients with stage B and C heart failure after anthracycline-based chemotherapy. We assessed the association between CMR, EKG, echocardiographic, serum, and clinical variables with adverse outcomes (cardiovascular death and admission for heart failure).

Results

We performed a clinically-indicated CMR study on 50 patients (52% male, mean age of 49 ± 16 years, anthracycline dose of 286 ± 89 mg/m2, and ejection fraction of 38 ± 9%) with AC-mediated cardiomyopathy. Patients presented a median of 45 months after chemotherapy and were followed for a median period of 28 months. LGE was an uncommon finding (3 patients, 6%). There was a strong inverse association between anthracycline dose and indexed left ventricular mass by CMR (r = -.75, p < 0.001, Figure 1). In univariate analysis, indexed LV-mass by CMR demonstrated the strongest unadjusted association with adverse events (hazard ratio: 0.75, chi-squared 26.2, p < 0.001). In a multivariable model, indexed LV-mass demonstrated the strongest association with the primary outcome (Figure 2).

figure1

Figure 1

figure2

Figure 2

Conclusions

Residual LV-mass measured by CMR is a powerful predictor of subsequent adverse cardiovascular events in patients with anthracycline-induced cardiotoxicity.

Funding

Dr. Neilan is supported by an NIH T32 Training Grant (T32HL09430101A1).

Author information

Correspondence to Tomas G Neilan.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Neilan, T.G., Pena-Herrera, D., Coelho-Filho, O.R. et al. Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy. J Cardiovasc Magn Reson 14, O30 (2012). https://doi.org/10.1186/1532-429X-14-S1-O30

Download citation

Keywords

  • Cardiomyopathy
  • Powerful Predictor
  • Adverse Outcome
  • Cardiac Magnetic Resonance
  • Late Gadolinium Enhancement